In addition to its crucial role as an oncology target, abnormal increase in the activity of PARP, especially PARP‐1, has been reported in conditions of neurodegenerative diseases, cancer, cardiovascular diseases, viral infections, and so on in preclinical studies.15, 16. This evidence concerns the gene PARP1 and neurodegenerative disease.